$450,000 of EXACT SCIENCES lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Support veteran access to guideline-recommended colorectal cancer screening. HR 842/S 339 support Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act: This bill allows, beginning in 2028, for Medicare coverage and payment for multi-cancer early detection screening tests that are approved by the Food and Drug Administration and that are used to screen for cancer across many cancer types, if the Centers for Medicare & Medicaid Services determines such coverage is appropriate. Coverage is limited to those under a certain age (age 68 in 2028, increased by one year every year thereafter) and to one test every 11 months. Support patient access to cancer screening and diagnostics. Support HR 1780/S 642 Finn Sawyer Access to Cancer Testing Act Support S 1410 Find It Early Act Support HR 2921/S 2745 Federal Firefighter Cancer Detection and Prevention Act of 2025 Support HR 1610 FIRE Cancer Act Support HR 4752/S 2760 Reducing Hereditary Cancer Act Support HR 7714 Colorectal Cancer Early Detection Act Support S 1717 Ensuring Patient Access to Critical Breakthrough Products Act"
You can find more data on corporate lobbying on Quiver Quantitative.
EXAS Insider Trading Activity
EXAS insiders have traded $EXAS stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $EXAS stock by insiders over the last 6 months:
- JAMES EDWARD DOYLE has made 0 purchases and 2 sales selling 3,485 shares for an estimated $182,399.
- KATHERINE S ZANOTTI sold 3,207 shares for an estimated $170,612
- JAMES HERRIOTT (SVP, General Counsel & Sec) sold 1,500 shares for an estimated $90,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EXAS Hedge Fund Activity
We have seen 262 institutional investors add shares of EXAS stock to their portfolio, and 277 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ added 2,969,613 shares (+inf%) to their portfolio in Q2 2025, for an estimated $157,805,234
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,700,607 shares (-42.2%) from their portfolio in Q2 2025, for an estimated $143,510,255
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 2,596,623 shares (-89.0%) from their portfolio in Q2 2025, for an estimated $137,984,546
- GOLDMAN SACHS GROUP INC added 1,486,137 shares (+204.1%) to their portfolio in Q2 2025, for an estimated $78,973,320
- HOLOCENE ADVISORS, LP added 1,404,086 shares (+189.5%) to their portfolio in Q2 2025, for an estimated $74,613,130
- BLACKROCK, INC. removed 1,388,121 shares (-11.6%) from their portfolio in Q2 2025, for an estimated $73,764,749
- STATE STREET CORP removed 1,234,872 shares (-18.7%) from their portfolio in Q2 2025, for an estimated $65,621,098
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
EXAS Analyst Ratings
Wall Street analysts have issued reports on $EXAS in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 10/22/2025
- Piper Sandler issued a "Overweight" rating on 10/08/2025
- Evercore ISI Group issued a "Outperform" rating on 10/07/2025
- Barclays issued a "Overweight" rating on 10/02/2025
- Craig-Hallum issued a "Buy" rating on 09/11/2025
- Baird issued a "Outperform" rating on 05/02/2025
To track analyst ratings and price targets for EXAS, check out Quiver Quantitative's $EXAS forecast page.
EXAS Price Targets
Multiple analysts have issued price targets for $EXAS recently. We have seen 9 analysts offer price targets for $EXAS in the last 6 months, with a median target of $68.0.
Here are some recent targets:
- Mark Massaro from BTIG set a target price of $75.0 on 10/22/2025
- David Westenberg from Piper Sandler set a target price of $70.0 on 10/08/2025
- Vijay Kumar from Evercore ISI Group set a target price of $68.0 on 10/07/2025
- Luke Sergott from Barclays set a target price of $65.0 on 10/02/2025
- Alex Nowark from Craig-Hallum set a target price of $85.0 on 09/11/2025
- Dan Leonard from UBS set a target price of $53.0 on 08/07/2025
- Conor McNamara from RBC Capital set a target price of $46.0 on 08/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
